X

Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 11 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NC 762 (Primary)
Indications Advanced breast cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions
Sponsors NextCure

Most Recent Events

27 Jun 2024 Priamary endpoint-Define a maximum tolerated dose (MTD) or pharmacologically active dose (PAD) removed from this trial.
01 Apr 2024 Status changed from active, no longer recruiting to discontinued.
19 Dec 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com